<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04664686</url>
  </required_header>
  <id_info>
    <org_study_id>265388</org_study_id>
    <nct_id>NCT04664686</nct_id>
  </id_info>
  <brief_title>Rate or Rhythm Control in CRT: the RHYTHMIC Study</brief_title>
  <acronym>RHYTHMIC</acronym>
  <official_title>Rate or Rhythm Control in CRT: the RHYTHMIC Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guy's and St Thomas' NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guy's and St Thomas' NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      70 patients with heart failure, AF and CRT with BiV&lt;95% will be randomised to either AF&#xD;
      ablation or AV node ablation. Evaluation at 6 months with echocardiography and clinical&#xD;
      assessment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      70 patients with heart failure, AF and CRT with BiV&lt;95% will be recruited from outpatient&#xD;
      clinic, pacing clinic or inpatient wards. Patients will be consented and will undergo&#xD;
      baseline investigation with a transthoracic 2D echocardiogram, ECG, blood tests, cardiac CT&#xD;
      with perfusion imaging, 6 minute walk test (6MWT), cardio-pulmonary exercise test (CPET) and&#xD;
      Minnesota Living with Heart Failure Questionnaire. Patients who are successfully screened&#xD;
      will be randomized 1:1 to receive AF catheter ablation rhythm control or AV-node ablation&#xD;
      rate control.&#xD;
&#xD;
      Ablation Procedure:&#xD;
&#xD;
      Patients will receive either AF catheter ablation or AV-node ablation during the procedure.&#xD;
      Patients randomised to AF catheter ablation will receive isolation of all four pulmonary&#xD;
      veins and additional lesions, considered indicated by the operator. The procedure will be&#xD;
      classified as successful if all four veins are isolated and the patient is in sinus rhythm.&#xD;
      Patients may undergo DC-cardioversion under sedation if they remain in atrial fibrillation.&#xD;
      AV-node ablation will be performed in line with current standard of care. Patients will also&#xD;
      undergo additional research investigations at the time of ablation as follows:&#xD;
&#xD;
      Acute Haemodynamic Study:&#xD;
&#xD;
      All patients will also undergo an acute haemodynamic study with pressure wire assessment of&#xD;
      both the right ventricle and the left ventricle at the start and end of the procedure. This&#xD;
      involves inserting pressure wires into the RV via a vein in the groin and into the LV via an&#xD;
      artery in the wrist or the groin. This will provide novel information on how AF catheter&#xD;
      ablation and AV-node ablation affect cardiac contractility.&#xD;
&#xD;
      Invasive Electroanatomical Mapping (Optional):&#xD;
&#xD;
      This is an optional additional procedure that patients may opt into at the time of&#xD;
      recruitment. This is performed during the ablation procedure with mapping catheters and&#xD;
      software which are CE marked and already in clinical use. Mapping of all four cardiac&#xD;
      chambers will be performed. This will be achieved via a vein and an artery in the groin. This&#xD;
      will provide novel information on how AF catheter ablation and AV-node ablation affect&#xD;
      electrical activation of the atria and ventricles.&#xD;
&#xD;
      Follow-up:&#xD;
&#xD;
      Patients will undergo a 2D transthoracic echocardiogram and ECG 1 week post ablation.&#xD;
      Patients will then be followed up at 6 months with 2D transthoracic echocardiogram, ECG,&#xD;
      clinical review, CPET, 6MWT, Minnesota Living with Heart Failure Questionnaire and pacing&#xD;
      check.&#xD;
&#xD;
      Patients in the AF catheter ablation group who have a recurrence of AF after a 3 month&#xD;
      blanking period will be permitted a re-do procedure. The follow-up investigations will take&#xD;
      place 6 months after the re-do procedure. If a patient has recurrence of AF after a second&#xD;
      ablation procedure and it is felt a third procedure is indicated, this will be performed&#xD;
      after the six month follow-up period has ended and the patient is no longer in the study.&#xD;
      They will be included in the intention-to-treat analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2021</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in ejection fraction</measure>
    <time_frame>6 months</time_frame>
    <description>On 2D echocardiography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in left ventricular end systolic volume</measure>
    <time_frame>6 months</time_frame>
    <description>On 2D echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in biventricular pacing percentage</measure>
    <time_frame>6 months</time_frame>
    <description>On pacemaker check</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in quality of life</measure>
    <time_frame>6 months</time_frame>
    <description>Assessed by Packer's Clinical Composite Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in NYHA class</measure>
    <time_frame>6 months</time_frame>
    <description>On clinical assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in heart failure symptoms</measure>
    <time_frame>6 months</time_frame>
    <description>Assessed by Minnesota Living with Heart Failure Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in 6-minute walk test</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in VO2 max</measure>
    <time_frame>6 months</time_frame>
    <description>Assessed via cardio pulmonary exercise test (CPET)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in AF burden</measure>
    <time_frame>6 months</time_frame>
    <description>Assessed via pacing check</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>AF catheter ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AV node ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>AF catheter ablation</intervention_name>
    <description>Isolation of all four pulmonary veins and additional lesions, considered indicated by the operator</description>
    <arm_group_label>AF catheter ablation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>AV node ablation</intervention_name>
    <description>AV node ablation</description>
    <arm_group_label>AV node ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to provide informed consent to participate and willing to comply with the&#xD;
             clinical investigation plan and follow-up schedule.&#xD;
&#xD;
          -  QRS duration &gt;120ms on surface ECG, severe left ventricular systolic impairment&#xD;
             (EFâ‰¤35%) and clinical symptoms of heart failure despite optimum medical therapy (NYHA&#xD;
             class II-IV) at time of CRT implant or upgrade&#xD;
&#xD;
          -  Successful CRT implant or upgrade including atrial lead&#xD;
&#xD;
          -  Biventricular pacing percentage &lt;95% secondary to atrial fibrillation at least 3&#xD;
             months post implant or upgrade&#xD;
&#xD;
          -  Clinically indicated for AV node ablation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Life expectancy &lt;1 year&#xD;
&#xD;
          -  Presence of atrial or ventricular thrombus&#xD;
&#xD;
          -  Permanent atrial fibrillation&#xD;
&#xD;
          -  Mechanical aortic valve replacement&#xD;
&#xD;
          -  Severe peripheral vascular disease&#xD;
&#xD;
          -  Female participants who are pregnant, lactating or planning pregnancy during the&#xD;
             course of the study.&#xD;
&#xD;
          -  Participation in other studies with active treatment / investigational arm&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher A Rinaldi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guys and St Thomas' NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christopher A Rinaldi</last_name>
    <phone>02071889257</phone>
    <email>aldo.rinaldi@kcl.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mark Elliott</last_name>
    <phone>02071889257</phone>
    <email>mark.elliott@kcl.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Guys and St Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Christopher A Rinaldi</last_name>
      <phone>02071889257</phone>
      <email>aldo.rinaldi@kcl.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Mark Elliott</last_name>
      <phone>02071889257</phone>
      <email>mark.elliott@kcl.ac.uk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 10, 2020</study_first_submitted>
  <study_first_submitted_qc>December 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2020</study_first_posted>
  <last_update_submitted>December 16, 2020</last_update_submitted>
  <last_update_submitted_qc>December 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

